Temodar — CareFirst (Caremark)
CNS metastases from solid tumors
Initial criteria
- Authorization may be granted for treatment of brain metastases due to solid tumors.
Reauthorization criteria
- Authorization may be renewed if there is no evidence of unacceptable toxicity or disease progression while on the current regimen.
Approval duration
12 months